Maximum IFN concentrations are decreased in severe patients. by Sonia T. Gazeau (21512764)

<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>" by Kira Shaw (18796168)

“…The following labelling information is also included in the file: animal ID, group ID (i.e. 2=WT, 1=AD, 3=ATH or MIX), sex (1=male, 2=female), session ID (corresponding to the experimental imaging day), and trial ID (corresponding to the order of detected locomotion events within each experimental imaging session). …”

Loss of Vps34 is associated with decreased eTreg survival but intact activation. by Erienne G. Norton (9612079)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Expression of lipid biosynthetic genes is decreased with polyamine depletion. by Yazmin E. Cruz-Pulido (20285238)

Experimental validation revealed that ACADSB and ACADM decreased in patients with UC. by Hongliang Chen (538815)

Supplementary Material for: Decreased Quality of Life in patients who desire Body Contouring Surgery after Bariatric Metabolic Surgery: A multicenter longitudinal analysis by Dijkhorst P.J. (20584910)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

K1 expression decreases in HA15 treated cells. by Guillermo Najarro (19964572)

Cancer virtual patients with decreased initial neutrophil concentrations have higher viral load peaks. by Sonia T. Gazeau (21512764)

“…<p><b>A)</b> Viral loads in mild <b>a</b><b>-c)</b> and severe virtual patients <b>d</b><b>-f)</b>. <b>B)</b> Sensitivity analysis determined that decreasing <i>N</i>0 (the initial concentration of neutrophils) causes higher peak viral load and peak IL-6 and IFN concentrations.…”

Lens profiles as Ez (orange lines) force was increased and Az and Pz (green lines) forces were decreased. by Ronald A. Schachar (16674576)